Diligence memo · auto-generated · as of July 2, 2026
ZS Pharma, Inc.
ZS Pharma, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
ZS Pharma, Inc. operates in Pharmaceuticals, based in Coppell.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ZS Pharma, Inc. has raised $68M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2012-10-09.
Most recent recorded round closed around 2014-02-28.
Valuation (modeled)modeled
Provath models ZS Pharma, Inc. at approximately $850M (range $53M–$3.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.25× the median modeled value of Series B Pharmaceuticals companies in 2013–2015 (42 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 12.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 86% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Lipocine Inc., CARDEAS PHARMA Corp, CoLucid Pharmaceuticals, Inc., Emisphere Technologies Inc, Vasculox, Inc..
Peoplefiled
23 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.